NCT01968616View on ClinicalTrials.gov

Ranibizumab Treatment for Retinal Vein Occlusion

NAUnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Macular Edema Due to BRVO/CRVO
Interventions
DRUG

Ranibizumab, 0.5mg, Intravitreal

Trial Locations (1)

Unknown

RECRUITING

Department of Ophthalmology, Kyoto University Hospital, Kyoto

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Kyoto University, Graduate School of Medicine

OTHER